Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer:Questions of choice

Journal of the Canadian Urological Association

Volumn 7, Issue 2 SUPPL.1, 2013, Pages

  Asselah, Jamil ^a   Sperlich, Catherine ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CSSS Charles Le Moyne   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874736504     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.274     Document Type: Review

References (19)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
5. Cornford P. Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer. Br J Med Surg Urol 2010;3:225-30.
6. Malik ZI. Cabazitaxel: evidence and clinical experience. Br J Med Surg Urol 2011;4(Suppl 1):S14-20
7. Saad F, Asselah J. Chemotherapy for prostate cancer: clinical practice in Canada. Can Urol Assoc J 2013;7:S5-S10. http://dx.doi.org/10.5489/cuaj.12284
8. Bahl A, Masson S, Malik Z, et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). J Clin Oncol 2012;30(Suppl):abstract 44.
9. Sridhar SS, Winquist E, Hubay S, et al. Cabazitaxel early access program (EAP) - Canadian interim results: safety, QOL, and utility values in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2012;23(Suppl 9):abstract 960.
10. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
11. Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011;29(Suppl):abstract LBA4517.
12. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012;30(Suppl):abstract LBA1.
13. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012;30(Suppl):abstract 8.
14. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
15. Abdulla A, Kapoor A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011;5:120-33.
16. Bahl A, Persad R. Metastatic castrate-resistant prostate cancer: new landscape, new challenges. Br J Med Surg Urol 2011;4(Suppl 1):S9-13.
17. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010;73:68-91.
18. Malik ZI, Montazeri AH, Wong H, et al. Post docetaxel treatment for castration-resistant prostate cancer (CRPC): does sequencing matter? J Clin Oncol 2012;30(Suppl):abstract e15135.
19. Francis J. Advances in treating metastatic castration-resistant prostate cancer. Cancer Nursing Practice;11:32-7.